Tonix Pharmaceuticals CEO purchases shares near yearly low
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Tonix Pharmaceuticals Chief Executive Seth Lederman purchased 5,000 common shares for $20,275 with the stock trading near 52-week lows. The purchase followed mixed third-quarter earnings featuring revenue beating expectations alongside a larger loss per share. For investors, insider buying at depressed valuation levels often signals executive confidence despite wider quarterly losses.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.